


## Etelcalcetide hydrochloride

<b>Cat. No.:</b>	HY-P1955A
<b>CAS No.:</b>	1334237-71-6
<b>Molecular Formula:</b>	C <sub>38</sub> H <sub>73</sub> N <sub>21</sub> O <sub>10</sub> S <sub>2</sub> ·17/2HCl
<b>Molecular Weight:</b>	1353.33
<b>Sequence Shortening:</b>	C1' . Ac-[d-Cys1]-[d-Ala]-[d-Arg]-[d-Arg]-[d-Arg]-[d-Ala]-[d-Arg]-NH <sub>2</sub> (Disulfide bridge: Cys1'-Cys1)
<b>Target:</b>	CaSR
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Sealed storage, away from moisture Powder    -80°C    2 years -20°C    1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (73.89 mM); Need ultrasonic					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		0.7389 mL	3.6946 mL	7.3892 mL
		<b>5 mM</b>		0.1478 mL	0.7389 mL	1.4778 mL
	<b>10 mM</b>		0.0739 mL	0.3695 mL	0.7389 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (73.89 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Etelcalcetide hydrochloride (AMG 416 hydrochloride) is a synthetic peptide as an activator of the calcium sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis <sup>[1]</sup> .
--------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### REFERENCES

[1]. Block GA, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA